ProEthic Pharmaceuticals announces acceptance of new drug application for migraine
December 12, 2007
ProEthic Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s submission of its New Drug Application for PRO-513 for the treatment of migraine headaches. PRO-513 is a patented formulation of diclofenac potassium powder for oral solution, which utilizes a unique, Dynamic Buffering Technology that has been demonstrated to enhance the pharmacokinetic profile of diclofenac. Story

Studies show effectiveness of EUFLEXXA(TM) in treating knee osteoarthritis and reducing the pain that interferes with daily activities
December 11, 2007
Ferring Pharmaceuticals presented the results of two studies on the effectiveness of EUFLEXXA(TM), an intra-articular hyaluronic acid for the relief of pain in knee osteoarthritis . One study showed that EUFLEXXA is equally effective in different radiographic stages of knee OA severity. The other demonstrated that, based on patients' perceptions, EUFLEXXA is effective in reducing the amount that knee OA pain interferes with patients' activities of daily livingand social/leisure activities, for up to six months. Story

American Academy of Pain Management is the nation's largest interdisciplinary organization serving clinicians who
treat people with pain through education, setting standards of care, and advocacy.
American Academy of Pain Management
13947 Mono Way #A • Sonora, CA 95370
www.aapainmanage.org